ImmuneOnco takes a second project pivotal
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
The month ahead: November’s upcoming events
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
